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Abstract: Endometriosis is a common gynecological disorder that has been associated with endome-
trial, breast and epithelial ovarian cancers in epidemiological studies. Since complex diseases are a
result of multiple environmental and genetic factors, we hypothesized that the biological mechanism
underlying their comorbidity might be explained, at least in part, by shared genetics. To assess
their potential genetic relationship, we performed a two-sample mendelian randomization (2SMR)
analysis on results from public genome-wide association studies (GWAS). This analysis confirmed
previously reported genetic pleiotropy between endometriosis and endometrial cancer. We present
robust evidence supporting a causal genetic association between endometriosis and ovarian cancer,
particularly with the clear cell and endometrioid subtypes. Our study also identified genetic variants
that could explain those associations, opening the door to further functional experiments. Overall,
this work demonstrates the value of genomic analyses to support epidemiological data, and to
identify targets of relevance in multiple disorders.
Keywords: endometriosis; hormone-related cancers; epithelial ovarian cancer; breast cancer; en-
dometrial cancer; mendelian randomization
1. Introduction
Endometriosis is a gynecological disorder affecting 190 million women worldwide.
The disease is characterized by the presence of endometrial-like tissue in extra-uterine
locations, causing pain and infertility [1]. Despite being a benign condition, growing
epidemiological evidence shows that women with endometriosis could be at increased
risk of developing certain types of hormone-related cancers, such as endometrial, breast or
epithelial ovarian cancer [2–5].
Regarding the link between endometriosis and endometrial cancer, several reports
describe that patients with endometriosis may be at higher risk for developing endometrial
cancer during their lifetime [6,7]. Moreover, a recent study reported that women with
endometriosis are more likely to be diagnosed with endometrial cancer at a younger age [8].
Data on the association between endometriosis and breast cancer are less consistent
due to different reasons that have been reviewed elsewhere [9,10]. On the one hand, some
studies provide evidence that women with endometriosis are more vulnerable to develop
breast cancer, although they show contradicting results with regard to the age when this
increased susceptibility is observed [11,12]. On the other hand, another group of studies are
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supportive of a negative association between endometriosis and breast cancer, the former
possibly conferring protection from the latter [13,14].
Ovarian cancer comprises a histologically and genetically broad range of tumors of
epithelial, sex cord-stromal and germ cell origin [15]. Epithelial ovarian cancer, which
represents 90% of all ovarian tumors, has a robust relationship with endometriosis [16–18].
Among the multiple epithelial ovarian cancer histotypes, endometriosis has been more
frequently linked to clear cell and endometrioid adenocarcinomas; in addition, literature
regarding the link between endometriosis and the serous subtype suggests that there is no
association between endometriosis and high-grade serous ovarian cancer, but there may
be an association with low-grade serous ovarian cancer [19–23]. However, more studies
are needed to draw definitive conclusions on whether these associations are indeed causal,
and what is the biology behind them.
Even though a link between endometriosis and the three aforementioned hormone-
related cancers exists, the underlying molecular mechanisms that explain this relationship
are less understood. In this sense, some reports describe that endogenous estrogen lev-
els [24] or immunological factors [25] might be involved in the malignant transformation of
endometriosis into hormone-related carcinomas. Besides these local environmental factors,
other studies suggest that genetic factors also play a pivotal role in the comorbidity between
endometriosis and hormone-related tumors. A recent cross-disease genetic correlation and
GWAS meta-analysis has described a moderate genetic correlation between endometriosis
and endometrial cancer, providing evidence of pleiotropy for some associated genetic
variants [26]. Similar reports have discovered loci shared between endometriosis and
most ovarian cancer histotypes, suggesting that the epidemiological association between
endometriosis and ovarian cancer is, at least in part, attributable to common genetic fac-
tors [27,28]. However, none of these genetic studies has explored whether, in addition to
shared genetic markers, endometriosis and hormone-related cancers might also be causally
linked through genetic factors using publicly available genetic data.
In this study, making use of public data from different genome wide association
studies (GWAS), we evaluated the genetic relationship between endometriosis and each
of those hormone-related cancers. Using genetic data, we assessed the potentially causal
associations between endometriosis and the hormone-related cancers using a two-sample
mendelian randomization (2SMR) strategy [29]. 2SMR is a statistical tool that helps to
identify causal associations between an exposure trait (i.e., endometriosis) and an outcome
trait (i.e., hormone-related cancers) of two independent populations by using single nu-
cleotide polymorphisms (SNPs) to mimic a randomized control trial. Moreover, additional
downstream tests extend our analysis to determine whether the exposure and the outcome
are linked through horizontal pleiotropy or present a high degree of heterogeneity. Our
results shed light on the shared genetic susceptibility between endometriosis and some
of the analyzed hormone-related cancers, and provide additional evidence for a causal
genetic influence of endometriosis on the development of epithelial ovarian cancer.
2. Results
2.1. 2SMR Analyses between Endometriosis and Hormone-Related Cancers Suggest a Potential
Causal Relationship between Endometriosis and Ovarian Cancer
Endometriosis has been associated with the susceptibility to suffer from certain
types of hormone-related cancers, including endometrial, breast and ovarian cancers.
In order to determine whether there is causality underlying this association, we per-
formed individual 2SMR analyses between endometriosis (exposure) and endometrial,
breast or ovarian cancers (outcomes) using SNPs as genetic instruments. Table 1 sum-
marizes the results from the 2SMR analysis for each cancer type. Each analysis was
carried out using three different methods: inverse variance weighted (IVW), weighted
median (WM) and Mendelian randomization Egger (MRE) (see Materials and Methods
section for further details). None of the methods was able to find any significant causal
relationship between endometriosis and breast cancer, and only the MRE method gave
a potential association between endometriosis and endometrial cancer, suggesting that
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some of the selected instruments are pleiotropic. Interestingly, we found evidence of a
significant causal relationship between endometriosis and ovarian cancer, not only with
the IVW method (Beta = 0.251, SE = 0.051, p-value = 9.34 × 10−7), but also with the WM
(Beta = 0.258, SE = 0.068, p-value = 1.37 × 10−4) and the MRE (Beta = 0.840, SE = 0.311, p-
value = 3.09 × 10−2) methods. The consistency of the effect reported by multiple methods
supports a causal relationship between endometriosis and ovarian cancer.
Table 1. Global 2SMR estimates between endometriosis endometrial, breast and ovarian cancers,
using the Sapkota et al. endometriosis GWAS as exposure. Estimates were calculated using the
inverse variance weighted (IVW), weighted median (WM), MR-Egger (MRE) methods. Beta (log
Odds Ratio), standard error (SE) and p-values are indicated. Significant associations (p-value < 0.05)
are highlighted in bold.
Outcome and
Method Beta SE p-Value
Endometrial cancer
IVW 0.100 0.118 0.400
WM 0.028 0.093 0.767
MRE 1.786 0.420 0.004
Breast cancer
IVW 0.001 0.045 0.987
WM 0.007 0.038 0.849
MRE −0.068 0.294 0.824
Ovarian cancer
IVW 0.251 0.051 9.34 × 10−7
WM 0.258 0.068 1.37 × 10−4
MRE 0.840 0.311 3.09 × 10−2
To validate our results, we replicated the analysis following the same criteria using
an independent endometriosis GWAS dataset from the UK Biobank (UKBB, ukb-b-10903,
“self-reported: endometriosis”) as exposure. As shown in Supplementary Table S1, even
with the small number of selected instruments (3 SNPs in total), this analysis still produced
significant results between endometriosis and ovarian cancer according to the IVW and WM
methods. The consistency across the two independent 2SMR analyses strongly supports
the potentially causal link between endometriosis and ovarian cancer.
In addition to the global 2SMR estimates, we also analyzed the role of selected instru-
ments in each hormone-related cancer at the single-SNP level (Figure 1). In the case of
endometrial and breast cancers, the SNPs showed both positive and negative beta values,
proposing that the risk to suffer from endometriosis and those cancers could be attributed
to different alleles of the same polymorphic sites. In turn, in the case of ovarian cancer,
the vast majority of SNPs showed consistent positive effects, indicating that those SNP
alleles that increase the susceptibility to endometriosis also predispose to suffer ovarian
cancer. Interestingly, in spite of the heterogeneous results, rs12037376 was the most signif-
icantly associated SNP across the three different analyses, with a positive beta value for
endometrial and ovarian cancer, but a negative beta value for breast cancer.
2.2. Sensitivity Analyses between Endometriosis and Hormone-Related Cancers Point to
Heterogeneity with Breast Cancer and Horizontal Pleiotropy with Endometrial Cancer
Next, we further explored the genetic relationship between endometriosis and the
three hormone-related cancers using different sensitivity analyses, including heterogeneity
and horizontal pleiotropy tests (Table 2). We found evidence for substantial heterogeneity
between endometriosis and breast cancer with both IVW and MRE (Cochran’s Q statistics
for IVW = 28.34, degrees of freedom [df] = 8, p-value = 0.0004, and Cochran’s Q’ statistics for
MRE = 28.12, df = 7, p-value = 0.0002). Similarly, the heterogeneity test between endometrio-
sis and endometrial cancer gave significant results with the IVW method (Cochran’s Q
statistics for IVW = 32.67, df = 8, p-value = 0.00007). A positive heterogeneity test is usually
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an indicator of potential violation of MR assumptions [29], and in this case show that the
Wald estimates in the breast and endometrial cancer analyses are heterogeneous.




Figure 1. Forest plots showing beta (± standard error) and p-values of the single-SNP 2SMR analysis between endometri-
osis and endometrial, breast and ovarian cancers. 
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netic relationship between endometriosis and endometrial cancer, rather than causal, is 
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Of note, there was no evidence of heterogeneity or horizontal pleiotropy between 
endometriosis and ovarian cancer, supporting the idea that the diseases might be linked 
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Figure 1. Forest plots showing beta (±standard error) and p-values of the single-SNP 2SMR analysis between endometriosis
and endometrial, breast and ovarian cancers.
Importantly, in the case of endometrial cancer, the Egger intercept was −0.171 ± 0.042,
and deviated significantly from zero (p-value = 0.0047). These results suggest that the
genetic relationship between ndometriosis and endometrial cancer, rather than causal, is
mor likely th result of significant horizontal pl iotropy.
Of n te, there was n evidence of heterogeneity or horizontal pleiotropy b tween
endometriosis and ovarian cancer, supporti g the idea that the diseases might be li ked
through a causal relationship, and not biased by horizontal pleiotropy.
2.3. 2SMR Estimates between Endometriosis and Ovarian Cancer Subtypes Suggest a Stronger
Causal Genetic Link between Endometriosis and Clear Cell and Endometrioid Histotypes
Our data show that the overall association between genetically predicted endometrio-
sis and ovarian cancer is strongly significant (IVW p-value = 9.34 × 10−7, see Table 1).
Given that endometriosis has been reported to be more strongly associated with certain
subtypes of ovarian cancer, especially clear cell and endometrioid, we decided to perform
a global 2SMR analysis using the different ovarian cancer histotype datasets as outcomes.
Supplementary Table S2 shows that, besides overall ovarian cancer, the top significant
associations were obtained for the clear cell (IVW p-value = 3.38 × 10−8) and endometrioid
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(IVW p-value = 5.08 × 10−4) histotypes. The scatter plots in Figure 2 and Supplementary
Figure S1 show the estimated effect sizes of the SNPs on both the exposure (endometriosis)
and the outcomes (ovarian cancer subtypes). The ascending slopes in all plots are indicative
of a positive correlation between endometriosis and those ovarian cancer subtypes. Overall,
our data strongly suggest that the comorbidity between endometriosis and ovarian cancer,
especially of clear cell and endometrioid subtypes, is mediated, at least in part, by a causal
genetic relationship.
Table 2. Sensitivity tests between endometriosis and endometrial, breast and ovarian cancer, using
the Sapkota et al. endometriosis GWAS as exposure. Significant associations (p-value < 0.05) are
highlighted in bold. Q: Cochran’s Q statistic; df: degrees of freedom.
Heterogeneity Test
Outcome and
Method Q Q_df p-Value
Endometrial cancer
IVW 32.67 8 0.00007
MRE 9.69 7 0.20671
Breast cancer
IVW 28.34 8 0.00041
MRE 28.12 7 0.00021
Ovarian cancer
IVW 7.12 8 0.52346
MRE 3.46 7 0.83951
Horizontal
Pleiotropy Test
Outcome Egger Intercept SE p-Value
Endometrial cancer −0.171 0.042 0.00472
Breast cancer 0.007 0.029 0.81924
Ovarian cancer −0.059 0.031 0.09719




Figure 2. Scatter plots for 2SMR analyses of the causal effect of endometriosis on overall, clear cell and endometrioid 
ovarian cancer (o. c.). The slope of the line corresponds to the estimated MR effect (beta value) calculated with the inverse 
variance weighted method. 
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garding endometriosis and endometrial cancer, our MR and sensitivity analyses provide 
evidence of heterogeneity and directional pleiotropy. These data indicate that the selected 
SNPs affect the outcome (endometrial cancer) through a pathway that is independent of 
the exposure (endometriosis). Our results are in line with a recently published genetic 
analysis where Painter et al. provided evidence for significant SNP pleiotropy between 
both diseases [26], and we discover some novel genetic variants, namely rs12037376 and 
rs10167914, that could play a role in both disorders. The concordance between the results 
from other groups and ours highlights the importance of performing additional sensitiv-
ity tests that not only evaluate the potential causality, but also the horizontal pleiotropy 
that is usually discarded as nuisance [30]. 
In the case of endometriosis and breast cancer, the Egger intercept was not signifi-
cantly different from zero, suggesting a lack of horizontal pleiotropy. However, the het-
erogeneity tests yielded significant results using both the IVW and MRE methods, indi-
cating substantial variation among the selected instruments. Of note, the global 2SMR es-
timates using all methods (IVW, WM and MRE) in the replication exposure dataset from 
the UKBB showed a negative beta value. These results, although not significant, are in 
accordance with the inverse association between endometriosis and breast cancer that has 
been observed in several epidemiological studies [13,14], and would further suggest that 
some genetic variants predisposing for the former would protect from the latter. How-
ever, given the few significant SNPs selected from the UKBB exposure dataset (see Table 
4), these results must be interpreted with caution. Indeed, other reasons might explain the 
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3. Discussion
Several epidemiological studies have reported comorbidity between endometriosis
and certain hormone-related cancers [2–5], but the molecular mechanisms underlying
those associations remain largely unexplored. Here, using public genetic data, we evaluate
the potential causal or pleiotropic relationships between these pathologies employing a
2SMR approach.
Our 2SMR analysis explores the genetic link between endometriosis and hormone-
related cancers and evaluates whether the associations observed could be causal or pleiotropic.
Combining all the significant endometriosis risk SNPs as selected instruments (see Table
4), our overall 2SMR analyses reveal a distinct relationship in each case. Regarding en-
dometriosis and endometrial cancer, our MR and sensitivity analyses provide evidence of
heterogeneity and directional pleiotropy. These data indicate that the selected SNPs affect
the outcome (endometrial cancer) through a pathway that is independent of the exposure
(endometriosis). Our results are in line with a recently published genetic analysis where
Painter et al. provided evidence for significant SNP pleiotropy between both diseases [26],
and we discover some novel genetic variants, namely rs12037376 and rs10167914, that
could play a role in both disorders. The concordance between the results from other groups
and ours highlights the importance of performing additional sensitivity tests that not only
evaluate the potential causality, but also the horizontal pleiotropy that is usually discarded
as nuisance [30].
In the case of endometriosis and breast cancer, the Egger intercept was not significantly
different from zero, suggesting a lack of horizontal pleiotropy. However, the heterogeneity
tests yielded significant results using both the IVW and MRE methods, indicating substan-
tial variation among the selected instruments. Of note, the global 2SMR estimates using all
methods (IVW, WM and MRE) in the replication exposure dataset from the UKBB showed
a negative beta value. These results, although not significant, are in accordance with
the inverse association between endometriosis and breast cancer that has been observed
in several epidemiological studies [13,14], and would further suggest that some genetic
variants predisposing for the former would protect from the latter. However, given the few
significant SNPs selected from the UKBB exposure dataset (see Table 4), these results must
be interpreted with caution. Indeed, other reasons might explain the underlying biology of
this possible protective effect; one of them is the long-term protection against breast cancer
that young women on danazol/GnRH agonist treatment for endometriosis have [11].
The most compelling finding is that our 2SMR analysis provides strong evidence of a
causal association between endometriosis and epithelial ovarian cancer. The consistency
of the estimates across methods using the Sapkota et al. and the UKBB endometriosis
GWAS as discovery and replication exposure datasets, respectively, strengthens this idea.
Furthermore, the non-significant p-values in the heterogeneity and horizontal pleiotropy
tests indicate that the MR assumptions are not violated. A more detailed MR analysis
focused on all reported epithelial ovarian cancer histotypes as outcome supports the idea
that endometriosis and clear cell and endometrioid ovarian cancers are more robustly
associated by a mechanism that involves shared genetics. Of note, the low-grade serous
ovarian cancer, whose association with endometriosis had been suggested in some studies,
yielded non-significant results in our 2SMR analysis.
Single SNP MR analysis using endometriosis as exposure and ovarian cancer as out-
come showed that the top significant SNPs are rs11674184 (2SMR p-value = 3.99 × 10−3)
and rs12037376 (2SMR p-value = 2.05 × 10−3), both of them with positive beta values. The
former is located within an intron of GREB1 on chromosome 2. Publicly available gene
expression data (https://gtexportal.org/home/; accessed in January 2021) indicate that
this SNP is a splicing quantitative trait loci (sQTL) of GREB1 in ovarian tissue with genome-
wide significance (p-value = 3.6 × 10−13). Similarly, rs12037376, located on 1p36.12, is
reported to be a sQTL of the long non-coding RNA LINC000339 in breast-mammary tissue
(p-value = 3.3 × 10−7) and an expression QTL (eQTL) of WNT4 at a suggestive significance
level (p-value = 0.05) in ovary. Genomic region 1p36.12 has been found to be associated
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with both endometriosis and ovarian carcinomas [28], and endometriosis risk alleles lo-
cated within that locus have been described to act through inverse regulation of nearby
genes such as CDC42 and LINC000339 [31]. To add more complexity, according to the En-
dometrial Tissue eQTL browser v2 (http://reproductivegenomics.com.au/shiny/eeqtl2/;
accessed in January 2021), rs12037376, the top SNP in our single-SNP MR analysis between
endometriosis and endometrial and breast cancers, is a strong cis-eQTL of LINC000339
(p-value ≈ 10−12) in endometrial tissue from women with endometriosis [32]. Future
studies should revisit our MR analyses to further explore the role that these individual
genetic variants might play in the regulation of both endometriosis and hormone-related
cancers. In particular, those future studies should address whether those SNPs that passed
the significance threshold are actually the causative polymorphism, or rather mediate
the association through a more complex regulatory mechanism involving, for instance,
regulation of gene expression.
Finally, although our in silico analyses provide robust evidence on the genetic asso-
ciation between endometriosis and certain types of hormone-related cancers, especially
epithelial ovarian cancer, the present study also has certain limitations. First, although the
use of available public genomic data is an efficient way to generate new hypotheses with
moderate costs, it also implies that the analyses must be adapted to the sample sizes and
ethnic groups of the existing published studies. In our case, although the sample sizes of
the available GWAS were large, our analysis used data from women of European ancestry
and one must be cautious when generalizing these findings to other ethnic groups. Second,
our results are still very preliminary, and should be interpreted with caution, pending
further experimental work to validate our conclusions.
4. Materials and Methods
4.1. GWAS Data Sources
In this study, we utilized either selected instruments or full summary statistics from
public GWAS on endometriosis and hormone-related cancers including endometrial, breast,
and epithelial ovarian cancer (referred to as “ovarian cancer” in this article) available in
NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/; accessed in January 2021) and
IEU GWAS database (https://gwas.mrcieu.ac.uk/; accessed in January 2021). Table 3 gives
a more detailed description of each dataset.
For the 2SMR analysis, selected instruments for endometriosis to be used as exposure
data were obtained either from the Sapkota et al. case-control study [33], or the UKBB cohort
study [34] available from the GWAS catalog or IEU GWAS database, respectively. The study
from Sapkota et al. is a meta-analysis of 11 independent endometriosis GWAS, the largest
case-control GWAS meta-analysis on this disease performed to date, and was used as the
discovery dataset; UKBB endometriosis data (ukb-b-10903, “self-reported: endometriosis”)
were used to replicate the results obtained in the discovery analyses. Regarding the
outcome data on hormone-related cancers, full summary statistics from either overall or
different cancer subtypes (see Table 3) were obtained from the largest and most recent
case-control GWAS published to date [35–37], available in the IEU GWAS database.
4.2. Two-Sample Mendelian Randomization (2SMR) Analysis
We conducted a two-sample mendelian randomization (2SMR) analysis using the
TwoSampleMR R package, setting endometriosis as exposure and the different hormone-
related cancers as outcomes. For the discovery analysis, we used the Sapkota et al. case-
control GWAS as exposure dataset, and each of the hormone-related female cancer GWASs
as independent outcome datasets. For the replication analysis, the UKBB cohort data was
used as exposure, and the same hormone-related female cancers as outcomes. In the case
of outcome data, we used each GWAS as an independent outcome. In addition to overall
ovarian cancer, we also explored its main clinical subtypes [37,38].
Int. J. Mol. Sci. 2021, 22, 6083 8 of 12
Table 3. Description of GWAS used in each analysis.




Discovery GWAS catalog GCST004549 208,641(17,045/191,596)
European and
Japanese 1 Sapkota, 2017 [33]
Replication IEU GWAS db ukb-b-10903 462,933(3809/459,124)
European
(UK) UKBB cohort [34]
Endometrial cancer (e. c.) GWAS catalog GCST006464 121,885(12,906/108,979) O’Mara, 2018 [35]
Breast cancer (b. c.) IEU GWAS db ieu-a-1126 228,951(122,977/105,974) European Michailidou, 2017 [36]
Ovarian cancer (o. c.) 2 Phelan, 2017 [37]
Overall o. c. IEU GWAS db ieu-a-1120 66,450(25,509/40,941) European
High grade serous o. c. IEU GWAS db ieu-a-1121 53,978(13,037/40,941) European
Low grade serous o. c. IEU GWAS db ieu-a-1122 41,953(1012/40,941) European
Invasive mucinous o. c. IEU GWAS db ieu-a-1223 42,358(1417/40,941) European
Clear cell o. c. IEU GWAS db ieu-a-1124 42,307(1366/40,941) European
Endometrioid o. c. IEU GWAS db ieu-a-1125 43,751(2810/40,941) European
High grade and low grade
serous o. c. IEU GWAS db ieu-a-1228
54,990
(14,049/40,941) European
Serous o. c.: low grade and
low malignant pot. IEU GWAS db ieu-a-1229
43,907
(2966/40,941) European
Serous o. c.: low
malignant pot. IEU GWAS db ieu-a-1230
42,895
(1954/40,941) European
Mucinous o. c.: invasive








potential o. c. IEU GWAS db ieu-a-1233
47,147
(3103/40,941) European
1 Only SNPs significant in European ancestry populations were considered for this study. 2 For simplicity, we refer to “epithelial ovarian
cancer” as “ovarian cancer” through the manuscript.
The genetic instruments to be used as exposure data were queried in MR base [29] and
formatted using the format_data or extract_instruments functions in TwoSampleMR. These
functions extract SNPs that are strongly associated with the exposure. In the case of the
GWAS by Sapkota et al., SNPs below the suggestive genome-wide significance value of
10−5 from the European Ancestry population were selected, and subsequently clumped into
11 independent instruments using the clump_data function (r2 < 0.001, window > 10,000 kb).
In the case of the UKBB “Non-cancer illness code, self-reported: endometriosis” dataset,
the 3 instruments selected were already clumped. Detailed information on the selected
SNPs in exposure data is shown on Table 4.
We retrieved summary-level data for the association of the selected instruments
and outcomes of interest using the extract_outcome_data function in TwoSampleMR, which
generated an outcome data-frame. This data-frame contains, among others, the beta,
standard error and p-values for the selected instruments that are present in the outcome
GWAS (see Supplementary Table S3); if the particular SNP is no available, a proxy is used.
The summary statistics for endometrial cancer were not available in the IEU GWAS database
so they were downloaded from the GWAS catalog and formatted to the requirements of the
TwoSampleMR package.
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Table 4. Summary information on endometriosis SNPs used as genetic instruments for the 2SMR
analysis. SNP: single nucleotide polymorphism; Chr.: chromosome; TSS: transcription start site; EAF:




1 Beta SE p-Value
Sapkota et al.
rs11674184 G/T 2 GREB1 0.39 −0.113 0.014 3 × 10−14
rs12037376 A/G 1 WNT4 0.17 0.131 0.020 1 × 10−12
rs1903068 A/G 4 KDR 0.68 0.104 0.016 2 × 10−11
rs12700667 A/G 7 Intergenic 0.74 0.086 0.016 2 × 10−8
rs1537377 C/T 9 CDKN2B-AS1 0.40 0.077 0.014 2 × 10
−8
rs71575922 G/C 6 SYNE1 0.16 0.104 0.021 2 × 10−8
rs74485684 T/C 11 FSHB 0.84 0.104 0.021 3 × 10−8
rs10167914 G/A 2 IL1A 0.30 0.104 0.018 5 × 10−8
rs760794 T/C 6 ID4 0.43 0.077 0.014 7 × 10−8
rs6546324 A/C 2 ETAA1 0.31 0.077 0.014 3 × 10−7
rs4762326 T/C 12 VEZT 0.47 0.068 0.014 1 × 10−6
UKBB
rs61768001 C/T 1 WNT4 0.16 0.002 0.0003 1 × 10−11
rs9992737 T/C 4 KDR 0.28 −0.001 0.0002 2 × 10−10
rs11031005 C/T 11 FSHB 0.14 −0.002 0.0003 1.5 × 10−9
1 The effect allele frequency from the European population is displayed.
Both the exposure and outcome data-frames were harmonized using the harmonise_data
function to remove ambiguous and/or palindromic SNPs, as it is the case for rs760794 and
rs4762326, which were excluded from the analysis.
The final data-frame was analyzed with the mr function using different methods. To
calculate the causal estimates between the exposure and the outcome, the inverse variance
weighted (IVW) method was used. IVW is the simplest way to obtain a MR estimate
using multiple SNPs, and treats each of them as a valid instrument. The fixed-effects
meta-analysis framework employed in this paper assumes that each SNP provides the
same estimate, or, in other words, that none of the SNPs exhibit horizontal pleiotropy.
Additionally, we calculated causal estimates with two other methods: the weighted median
(WM), and that the Mendelian randomization Egger (MRE) method. The WM is an
alternative approach that takes the median effect of all available SNPs. This has the
advantage that only 50% of the SNPs need to be valid instruments (no horizontal pleiotropy,
no association with confounders, strong association with the exposure). It can be obtained
by weighting the contribution of each SNP by the inverse variance association with the
outcome. The MRE method relaxes the assumption of no horizontal pleiotropy, and adapts
the IVW analysis by allowing a non-zero intercept and the net horizontal pleiotropic effect
across all SNPs to be directional. Thus, it allows one or all of the SNPs used as instruments
to be pleiotropic.
Scatter plots were generated using the mr_scatter_plot function. Additionally, the MR
estimate of each individual SNP was obtained using singlesnp_mr, a function that calculates
the Wald Ratio of every genetic variant, and was plotted using the mr_forest_plot function
in TwoSampleMR.
We also performed additional sensitivity analyses. On the one hand, we carried out a
heterogeneity test using the mr_heterogeneity function, and on the other hand, we calculated
the MR-Egger intercept, which is an indication of the net directional pleiotropy, using the
mr_pleiotropy_test function.
The R scripts generated for this analysis are available in the Supplementary Materials.
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5. Conclusions
Our study confirms the association between endometriosis and some hormone-related
cancers and provides further evidence of a shared genetic etiology. Our 2SMR analysis
further confirms that endometriosis and endometrial cancer are linked by a pleiotropic
association, but gives inconclusive results about breast cancer, in line with previous lit-
erature. Importantly, we demonstrate that the association between endometriosis and
ovarian cancer, especially of clear cell and endometrioid subtypes, is caused, at least in
part, by a shared genetic origin. Up to date, it has been widely accepted that patients
with endometriosis need to be regularly checked to prevent malignant transformation into
certain hormone-related carcinomas, especially to epithelial ovarian cancer. Our results go
beyond this idea, and propose that a common genetic makeup might also contribute, at
least in part, to the increased malignancy.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22116083/s1, Figure S1: Scatter plots for MR analyses of the causal effect of endometriosis
on several subtypes of ovarian cancer; Table S1: Global 2SMR estimates between endometriosis and
endometrial, breast and ovarian cancer, using UKBB endometriosis GWAS as exposure; Table S2:
Global 2SMR estimates between endometriosis and ovarian cancer subtypes, using the Sapkota et al.
endometriosis GWAS as exposure; Table S3: Summary information on Beta, Standard Error (SE) and p-
values of genetic instruments from Sapkota et al. and UKBB exposure datasets in endometrial, breast
and ovarian cancer GWASs used as outcome datasets. Supplementary file 1: R scripts generated for
2SMR analysis.
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